Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 1745108, 7 pages
http://dx.doi.org/10.1155/2016/1745108
Clinical Study

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

1Department of Respirology, Kyoto Prefectural University of Medicine, Kyoto, Japan
2Sendai Kousei Hospital, Sendai, Japan
3Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
4Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan
5Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
6Department of Surgery, Kurume University School of Medicine, Kurume, Japan
7Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
8Kanagawa Cancer Center Research Institute, Yokohama, Japan
9Biostatistics Center, School of Medicine, Kurume University, Kurume, Japan
10Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
11Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
12Division of Clinical Research, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
13Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan

Received 25 January 2016; Accepted 7 April 2016

Academic Editor: Senthamil Selvan

Copyright © 2016 Koichi Takayama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” The New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. F. V. Fossella, R. DeVore, R. N. Kerr et al., “Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens,” Journal of Clinical Oncology, vol. 18, no. 12, pp. 2354–2362, 2000. View at Google Scholar · View at Scopus
  3. K. Itoh and A. Yamada, “Personalized peptide vaccines: a new therapeutic modality for cancer,” Cancer Science, vol. 97, no. 10, pp. 970–976, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Hattori, T. Mine, N. Komatsu et al., “Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1843–1852, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Yanagimoto, H. Shiomi, S. Satoi et al., “A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients,” Oncology Reports, vol. 24, no. 3, pp. 795–801, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Noguchi, T. Kakuma, H. Uemura et al., “A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. 1001–1009, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Yoshiyama, Y. Terazaki, S. Matsueda et al., “Personalized peptide vaccination in patients with refractory non-small cell lung cancer,” International Journal of Oncology, vol. 40, no. 5, pp. 1492–1500, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Komatsu, S. Shichijo, M. Nakagawa, and K. Itoh, “New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 64, no. 6, pp. 535–545, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Maruyama, Y. Nishiwaki, T. Tamura et al., “Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4244–4252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Takeda, S. Negoro, T. Tamura et al., “Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104),” Annals of Oncology, vol. 20, no. 5, pp. 835–841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Kawaguchi, M. Ando, K. Asami et al., “Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: docetaxel and erlotinib lung cancer trial (DELTA),” Journal of Clinical Oncology, vol. 32, no. 18, pp. 1902–1908, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Sharma, K. Wagner, J. D. Wolchok, and J. P. Allison, “Novel cancer immunotherapy agents with survival benefit: recent successes and next steps,” Nature Reviews Cancer, vol. 11, no. 11, pp. 805–812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. M. Forde, R. J. Kelly, and J. R. Brahmer, “New strategies in lung cancer: translating immunotherapy into clinical practice,” Clinical Cancer Research, vol. 20, no. 5, pp. 1067–1073, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Brahmer, K. L. Reckamp, P. Baas et al., “Nivolmab versus docetaxel in advanced squamous-cell non-small-cell lung cancer,” The New England Journal of Medicine, vol. 373, pp. 123–135, 2015. View at Google Scholar
  15. T. Sasada, M. Noguchi, A. Yamada, and K. Itoh, “Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer,” Human Vaccines and Immunotherapeutics, vol. 8, no. 9, pp. 1309–1313, 2012. View at Publisher · View at Google Scholar · View at Scopus